The CHEO Research Institute and Bruyère are two organizations with a proven track record of fostering innovation by connecting research, industry, and health care leaders.  With a mission to solve challenges that impact youth and older adult care through innovative solutions, the 8-80 Collaborative was launched. The two organizations will work together to support innovators, new ideas and health-tech products and services that directly address some of the most pressing problems faced by health care organizations, clinicians and researchers.

Carleton University is a dynamic, research-intensive institution that engages in partnerships to address the world’s most pressing challenges. The university’s corporate collaborations bring together world-class companies, researchers and a new generation of talent with over 30,000 students to deliver innovations and results that are driving a more prosperous, sustainable future. Carleton is pleased to be a founding institutional partner of Capital BioVentures.

Capital BioVentures is an Accelerator Program that removes hurdles for our Canadian innovators, while fostering a collaborative and cohesive ecosystem in the National Capital Region. The program brings together lab space, seasoned biotech expertise, and funding to help our biotech firms scale.

Esphera SynBio is developing engineered exosomes for the delivery of specific payloads to target cells using their first-in-class proprietary multimeric fusion protein design.

NuvoBio's main goal is to find smart ways of using technology that accelerate drug development and minimize off-target risk. NuvoBio has active peptide drug development programs in oncology and infectious disease.

The Queen’s innovation ecosystem is enabled (and fueled) by research talent, funding investments, and facilities partnerships and training opportunities for discovery, innovation, and knowledge mobilization. With 1,100+ faculty and clinician faculty (including more than 35 Canada Research Chairs), the academy continues to solve some the world’s largest challenges. Queen’s seeks external funding and invests in research to leverage faculty and student talent towards a common goal that benefits Eastern Ontario and beyond. Our broad range of curiosity driven research centres brings together the academy from various disciplines to collaboratively generate new knowledge. The outcomes from this research environment (people & platforms) are partnerships with local, regional and national private sector entities, together with the potential for new start-ups to commercialize innovations. Queen’s creates the conditions necessary for startups to grow in Eastern Ontario.

The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, SCN’s goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has grown from a few dozen labs to more than 270 world-class research groups, supporting over 250 research projects and 30 clinical trials. Since its inception, over 25 biotech companies have been catalyzed or enhanced and more than 6,400 highly qualified personnel have been trained. In 2021, the Government of Canada demonstrated its continuing trust and support in SCN with an investment of $45 million for the 2022–2025 period.

University Health Network (UHN) is Canada’s largest research hospital and is consistently ranked number one on the list of Canada's Top Research Hospitals. UHN has strengths in immunology and cell-based cancer therapies.

The University of Waterloo a leading global research-intensive university, renowned for entrepreneurship and innovation, providing co-op and work-integrated learning at scale with impact. The University continues to spur innovation to solve problems on a global scale

Velocity accelerates founders from idea to commercialization and beyond. With access to unmatched resources, laboratory and collaboration space, funding, and an expansive and experienced network, over 400 startups have netted more than $US26 billion in enterprise value since Velocity's inception at the University of Waterloo, Canada’s top university for founders.